MarketPeel
Insider Trading Intelligence
GM

Gene Mack

GANX
CHIEF FINANCIAL OFFICER · GAIN THERAPEUTICS, INC. · CIK 0001737979
FILING MIX · LIFETIME100%/0%
BUYS
5
SELLS
0
TOTAL VALUE
$14.5K
COMPANIES
1
ACTIVE SINCE
Apr 2024
HOLDINGS NOW
200,000
AVG SELL PX
TRADE KIND
SHOWING 5 / 5
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
1 backtested trades · 8 horizons · 1 pending
Forward-return performance of every backtestable P/S trade by Gene Mack, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d1+100.00%+34.50%+4.00%+30.50%+30.50%
14d1+100.00%+31.45%+5.47%+25.98%+25.98%
30d1+100.00%+18.20%+2.52%+15.68%+15.68%
60d1+100.00%+101.75%+7.87%+93.88%+93.88%
90d1+100.00%+127.23%+12.09%+115.14%+115.14%
180d1+100.00%+148.62%+14.09%+134.53%+134.53%
1y1+100.00%+50.80%+20.68%+30.13%+30.13%
2y1(1 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
GANX · 200,000 shares · as of Mar 24, 2026
067,831135,663203,494271,32520252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 5 buys / 0 sellsCOVERAGE · 8 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
GANX
GAIN THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
200,000200,000Mar 24, 2026Mar 26, 2026View →
GANX
GAIN THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
200,000200,000Mar 20, 2025Mar 21, 2025View →
GANX
GAIN THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
271,325271,325Jan 6, 2025Jan 7, 2025View →
GANX
GAIN THERAPEUTICS, INC.
PURCHASE
CFO and Interim CEO
14,400$1.01$14.5K14,400Aug 9, 2024Aug 12, 2024View →
GANX
GAIN THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
200,000200,000Apr 8, 2024Apr 8, 2024View →
Other insiders · GANX
Loading peer insiders…
About this filer
CIK 0001737979
ROLE
Chief Financial Officer
PRIMARY
GANX
COMPANIES
1
ACTIVE SINCE
Apr 2024
MARKETPEEL · /INSIDER/0001737979DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback